CL
RNA

CRCM LP’s Atrium Therapeutics RNA Stock Holding History

CRCM LP’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.84M Buy
+583,255
New +$7.62M 5.44% 3

Other funds holding RNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
CDMG
Creek Drive Management Group San Francisco, California $206M AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return

CRCM LP's RNA Position: Q2 2026 in Review

CRCM LP opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 583,255 shares worth $7.84M. The stake represents 5.44% of the portfolio and ranks #3 among its holdings.

79 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • CRCM LP held 583,255 shares of Atrium Therapeutics worth $7.84M as of Q2 2026.
  • Atrium Therapeutics was a new CRCM LP position in Q2 2026.
  • Atrium Therapeutics made up 5.44% of CRCM LP's portfolio in Q2 2026, its #3 holding.
  • 79 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on CRCM LP's 13F filing for Q2 2026, filed 12 Aug 2026.